Information Provided By: 
Fly News Breaks for February 25, 2019
ALDR
Feb 25, 2019 | 20:23 EDT
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $28 price target on Alder Biopharmaceuticals after its Q4 results and update on eptinezumab this evening. The analyst maintains a positive view on the program and contends that "eptinezumab is the best suited agent for the most debilitated migraine patients", adding that the company could generate peak revenues of over $1B if it were to capture just the severe subset of patients.
News For ALDR From the Last 2 Days
There are no results for your query ALDR
